Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia.
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ metabolism
Cohort Studies
Female
Follow-Up Studies
Humans
Leukemia, Myeloid, Acute
/ drug therapy
Male
Middle Aged
Prognosis
Proto-Oncogene Proteins c-kit
/ metabolism
Survival Rate
Young Adult
fms-Like Tyrosine Kinase 3
/ metabolism
CD117
CD135
Flow-cytometry
acute myeloid leukemia
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 09 2019
01 09 2019
Historique:
received:
15
10
2018
entrez:
27
9
2019
pubmed:
27
9
2019
medline:
27
2
2020
Statut:
epublish
Résumé
Background: The key proliferative RTKs for AML include c-KIT receptor (CD117) and FLT-3 receptor (CD135).
The aim of this study was to evaluate the CD135 and CD117 expression, co-expression of CD135 and CD117
(CD135+CD117), and the association of that co-expression with Event Free Survival (DFS) and Overall Survival (OS)
rates. Material and Methods: We analyzed CD117 and CD135 expression on AML blasts by flow cytometry and its
association with Event Free Survival (DFS) and Overall Survival (OS) in 66 AML treated on Hematology-Oncology
Research Center, Iran, Tabriz. Results: The overall OS and EFS were 50% and 80.3% respectively during our study.
Cox-regression analysis revealed that a poor EFS was significantly associated a low CD135 (HR 0.34, 95% CI
0.13–0.88, P = 0.02). Conclusion: This is the first study from Iran to show that the expressions of CD135, CD117 is
easily measurable by routine diagnostic flow-cytometry, and CD135+117 were not significantly associated with CR,
EFS, or OS .
Identifiants
pubmed: 31554356
doi: 10.31557/APJCP.2019.20.9.2625
pmc: PMC6976829
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
FLT3 protein, human
EC 2.7.10.1
KIT protein, human
EC 2.7.10.1
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2625-2631Références
Annu Rev Biochem. 2000;69:373-98
pubmed: 10966463
Blood. 1991 Jul 1;78(1):30-7
pubmed: 1712644
Curr Hematol Malig Rep. 2009 Apr;4(2):77-82
pubmed: 20425418
Blood Cells Mol Dis. 2016 Mar;57:74-80
pubmed: 26852660
Cytometry B Clin Cytom. 2013 Nov-Dec;84(6):390-7
pubmed: 23740774
Eur J Haematol. 2004 Feb;72(2):89-106
pubmed: 14962246
Leukemia. 1994 Feb;8(2):258-63
pubmed: 7508533
Blood. 2008 Apr 1;111(7):3849-58
pubmed: 18245664
Blood. 1998 Jul 15;92(2):596-9
pubmed: 9657760
Cytometry B Clin Cytom. 2003 Mar;52(1):40-3
pubmed: 12599181
Leuk Res. 1988;12(11-12):923-8
pubmed: 3216673
Int J Biochem Cell Biol. 1999 Oct;31(10):1053-74
pubmed: 10582339
Cell Signal. 2009 Dec;21(12):1717-26
pubmed: 19540337
Nature. 1997 Apr 24;386(6627):761, 763
pubmed: 9126728
Clin Cancer Res. 2017 Jul 15;23(14):3649-3656
pubmed: 28108543
Blood. 2004 Jul 15;104(2):558-60
pubmed: 15044257
Blood Cells Mol Dis. 2015 Jan;54(1):56-64
pubmed: 25216797
Oncogene. 2000 Nov 20;19(49):5548-57
pubmed: 11114734
Am J Clin Pathol. 1996 Aug;106(2):192-5
pubmed: 8712172
Blood. 1996 Feb 1;87(3):1089-96
pubmed: 8562934
Clin Cancer Res. 2004 Feb 15;10(4):1241-9
pubmed: 14977821
Leukemia. 1996 Apr;10(4):588-99
pubmed: 8618433